Oncology
Latest news
915 articles · 20 / page
MDASI-HN Symptom Profiling for Early Risk Stratification of Hypoglossal Neuropathy in Oropharyngeal Cancer Survivors
This study found that patient-reported speech/voice and related head-and-neck symptoms can help predict hypoglossal neuropathy risk after oropharyngeal cancer treatment, supporting earlier surveillance with the MDASI-HN-NERVE score.
Immune Checkpoint Inhibitors Deliver Durable Responses in MSI-H Gastroesophageal Adenocarcinoma
MSI-H/dMMR gastroesophageal adenocarcinoma showed high response rates to immune checkpoint inhibitors, including durable complete responses in locoregional disease that may support carefully selected nonoperative management.
Checkpoint Blockade Delivers Deep, Durable Responses in MSI-H Gastroesophageal Adenocarcinoma
This single-center cohort found high and durable checkpoint inhibitor responses in dMMR/MSI-H gastroesophageal adenocarcinoma, including complete responses in locoregional disease that may support carefully selected nonoperative management.
GLP-1 Receptor Agonists May Outperform Bariatric Surgery for Breast Cancer Outcomes in Obese Postmenopausal Women
In a large TriNetX study, GLP-1 receptor agonists were associated with better overall survival and lower locoregional recurrence than bariatric surgery alone in obese postmenopausal women with stage 0-III breast cancer.
Prehabilitation During Neoadjuvant Chemotherapy May Improve Surgery Eligibility and Chemotherapy Delivery in Advanced Ovarian Cancer
A matched-cohort study found that multimodal prehabilitation during neoadjuvant chemotherapy improved chemotherapy delivery and increased the chance of interval debulking surgery in advanced ovarian cancer, with the strongest benefits seen
SPP1-Positive Macrophages Shape Immunosuppression in Colorectal Cancer Lymph Nodes
Single-cell profiling of colorectal cancer lymph nodes revealed an SPP1–CD44–NF-κB1 pathway that promotes CD137+ regulatory T-cell maturation and may be therapeutically targetable.
Gestational Diabetes and Later Cancer Risk: Reassuring Overall Results, but a Kidney Cancer Signal Emerges
A Danish registry study found no overall increase in selected cancers after gestational diabetes, but did observe a small absolute and relative increase in kidney cancer risk.
Avelumab Plus Methotrexate in Low-Risk Gestational Trophoblastic Tumors: A Promising First-Line Signal From TROPHAMET
TROPHAMET found that first-line avelumab plus methotrexate achieved 96.2% hCG normalization in low-risk gestational trophoblastic tumors with manageable toxicity, no relapses at 41 months, and preserved fertility.
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
This case report details successful management of RET-altered medullary thyroid carcinoma using tarlatamab after selpercatinib progression, highlighting modified dosing to mitigate toxicities and achieve complete response.
Blood Cancer Proteins Plus Histoplasma Antibodies Improve Malignancy Assessment in Indeterminate Pulmonary Nodules
In two US cohorts, combining serum cancer biomarkers and Histoplasma antibodies with the Mayo model improved discrimination of benign versus malignant pulmonary nodules, especially in intermediate-risk cases.
Pelvic Exenteration for Recurrent Cervical Cancer Can Deliver Long-Term Survival, but Survivorship Burden Remains Substantial
A mixed-methods study suggests pelvic exenteration offers meaningful long-term survival in selected patients with recurrent cervical cancer, while qualitative data reveal persistent physical, social, and sexual burdens that standardized qua
A Novel Approach to Targeting DLL3 with Tarlatamab in a Patient with Medullary Thyroid Carcinoma after Progression on Selpercatinib
A 64-year-old man with RET-altered medullary thyroid carcinoma who progressed on selpercatinib achieved complete response after modified dosing of tarlatamab with manageable CRS/ICANS.
Fovinaciclib for First-Line Therapy of Advanced Breast Cancer: A Randomized Clinical Trial
Adding fovinaciclib to first-line aromatase inhibitor therapy significantly prolonged progression-free survival in advanced hormone receptor-positive, ERBB2-negative breast cancer, with manageable safety and no clear quality-of-life loss.
Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations
Population-based testing for breast cancer pathogenic variants identified many women who would not have been flagged by clinical or polygenic risk models, supporting its role in risk-based screening.
Longitudinal Risk for Suicidal Self-Directed Violence Among Veterans With Cancer
A large study of veterans with cancer found persistent risk of suicidal self-directed violence, especially in younger, unmarried, frail, or mentally ill patients and those with central nervous system, head and neck, or thyroid cancers.
Intraperitoneal and Intravenous Paclitaxel Plus S-1 for Gastric Cancer With Peritoneal Metastasis: Phase 3 Trial
A phase 3 trial found that adding intraperitoneal paclitaxel to intravenous paclitaxel plus S-1 improved survival in gastric cancer with peritoneal metastasis without increasing severe toxicity.
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results From the DOREMY Phase 2 Trial
Long-term follow-up from the DOREMY phase 2 trial shows that reduced-dose preoperative radiotherapy for localized myxoid liposarcoma achieved excellent local control with relatively low toxicity.
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: Long-Term Results from the Phase 2 DOREMY Trial
A long-term phase 2 trial found that reduced-dose preoperative radiotherapy followed by surgery provided excellent local control and acceptable toxicity in localized myxoid liposarcoma.
The Oncology Care Model and Starting Systemic Therapy for Cancer
A Medicare-based study found the Oncology Care Model did not increase systemic therapy starts for newly diagnosed cancer and was linked to less treatment initiation and lower spending in poor-prognosis cancer.
Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study
This WISDOM Study analysis found that most women with breast cancer pathogenic variants would not have been flagged for high-risk screening by clinical or polygenic risk models alone, supporting population-based genetic testing.
Browse by specialty
Open language-specific specialty feeds and department pages.